Compugen Ltd. (CGEN) P/E Ratio History
UndervaluedTrading at 5.3x vs 5Y avg 27.4x · 25th percentile · Below historical baseline · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of November 9, 2026, Compugen Ltd. (CGEN) trades at a price-to-earnings ratio of 5.3x, with a stock price of $1.96 and trailing twelve-month earnings per share of $0.37.
The current P/E is 81% below its 5-year average of 27.4x. Over the past five years, CGEN's P/E has ranged from a low of 4.1x to a high of 93.8x, placing the current valuation at the 25th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, CGEN trades at a 79% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, CGEN trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CGEN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CGEN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CGEN P/E vs Peers
Immuno-Oncology & Cancer Vaccines peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 7.1Lowest | 0.69Best | +817%Best | |
| $298M | 21.2 | - | +100% | |
| $32B | 36.7 | 8.67 | +171% | |
| $258B | 36.4 | 17.23 | +7% | |
| $4B | 33.6 | - | -143% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CGEN Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $2.14 | $0.38 | 5.7x | -79% |
| FY2026 Q1 | - | $2.13 | $0.37 | 5.8x | -79% |
| FY2025 Q4 | Dec 31 2025 | $1.53 | $0.37 | 4.1x | -85% |
| FY2024 Q3 | Sep 30 2024 | $1.81 | $0.02 | 93.8x | +243% |
Average P/E for displayed period: 27.4x
CGEN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CGEN — Frequently Asked Questions
Quick answers to the most common questions about buying CGEN stock.
What is CGEN's P/E ratio?
Compugen Ltd. (CGEN) trailing twelve-month P/E ratio is 5.3x, based on TTM diluted EPS of $0.37. The 5-year average P/E is 27.4x and the historical range spans 4.1x to 93.8x.
Is CGEN stock overvalued or undervalued?
CGEN trades at 5.3x P/E, below its 5-year average of 27.4x. At the 25th percentile of its historical range (4.1x–93.8x), the stock is priced at a discount to its own history.
Is CGEN stock expensive?
No, CGEN is not expensive on a historical basis. The current P/E of 5.3x is below the 5-year average of 27.4x and sits at the 25th percentile of its valuation range.
What is CGEN's historical P/E range?
Over the past 5 years, CGEN's P/E ratio has ranged from 4.1x to 93.8x, with a median of 5.8x and an average of 27.4x. The current P/E of 5.3x places the stock at the 25th percentile of this range. Full historical data spans 2024–2026.
How does CGEN's P/E compare to the S&P 500?
CGEN trades at 5.3x P/E versus the S&P 500 median of 21.8x. The 76% discount to the market suggests lower growth expectations or perceived higher risk.
How does CGEN's valuation compare to Healthcare peers?
Compugen Ltd. P/E of 5.3x compares to the Healthcare sector median of 24.6x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CGEN's PEG ratio?
CGEN PEG ratio is N/A, based on a P/E of 5.3x and EPS growth of 337.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CGEN's earnings yield?
CGEN earnings yield is 18.97%, the inverse of its 5.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.